Literature DB >> 17443284

Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy.

Tameyoshi Yamamoto1, Hiroaki Nagano, Yasuharu Imai, Kazuto Fukuda, Hitoshi Matsumoto, Motoi Kondo, Hideo Ota, Masato Nakamura, Hiroshi Wada, Takehiro Noda, Bazarragchaa Damdinsuren, Keizo Dono, Koji Umeshita, Shoji Nakamori, Masato Sakon, Kenichi Wakasa, Morito Monden.   

Abstract

We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration. The patient was a 50-year-old man with hepatitis C virus and HCC. The tumors consisted of a 5-cm main nodule in the right lobe (segment 8) and multiple intrahepatic metastases. The tumor also involved portal vein thrombosis throughout the right portal branch. After two cycles of interferon-alpha/5-fluorouracil combination chemotherapy, tumor markers demonstrated a decreasing tendency. Nine months after the initiation of this therapy, the tumors were limited to the right lobe and were surgically removed by S8 subsegmentectomy, S5 partial hepatectomy, and portal thrombectomy. The serum levels of both alpha-fetoprotein and protein induced by vitamin K absence II fell to normal levels after hepatic resection. Fifty-eight months after the first treatment, he is alive with several recurrent nodules in the liver. In conclusion, the interferon-alpha/5-fluorouracil combination therapy is a useful treatment for HCC in patients who have multiple intrahepatic metastases and portal vein thrombosis. In addition to this therapy, combined modality therapy including, for example, surgical resection, can sometimes have a dramatic therapeutic effect, shown by tumor markers reverting to normal levels.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17443284     DOI: 10.1007/s10147-006-0630-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  21 in total

Review 1.  Ablative techniques for hepatocellular carcinoma.

Authors:  C C Barnett; S A Curley
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

2.  Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein.

Authors:  J Fan; Z Q Wu; Z Y Tang; J Zhou; S J Qiu; Z C Ma; X D Zhou; S L Ye
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

3.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.

Authors:  Masato Sakon; Hiroaki Nagano; Keizo Dono; Shoji Nakamori; Koji Umeshita; Akira Yamada; Sumio Kawata; Yasuharu Imai; Shohei Iijima; Morito Monden
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

5.  Expression of interferon alpha/beta receptor in human hepatocellular carcinoma.

Authors:  M Kondo; H Nagano; M Sakon; H Yamamoto; O Morimoto; I Arai; A Miyamoto; H Eguchi; K Dono; S Nakamori; K Umeshita; K Wakasa; Y Ohmoto; M Monden
Journal:  Int J Oncol       Date:  2000-07       Impact factor: 5.650

6.  Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells.

Authors:  H Eguchi; H Nagano; H Yamamoto; A Miyamoto; M Kondo; K Dono; S Nakamori; K Umeshita; M Sakon; M Monden
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

Review 7.  Hepatocellular carcinoma: diagnosis and treatment.

Authors:  Alex S Befeler; Adrian M Di Bisceglie
Journal:  Gastroenterology       Date:  2002-05       Impact factor: 22.682

8.  Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy.

Authors:  I Ikai; Y Yamaoka; Y Yamamoto; N Ozaki; Y Sakai; S Satoh; N Shinkura; M Yamamoto
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

9.  Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression.

Authors:  D W Shen; Y G Lu; K V Chin; I Pastan; M M Gottesman
Journal:  J Cell Sci       Date:  1991-03       Impact factor: 5.285

10.  Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.

Authors:  H Ota; H Nagano; M Sakon; H Eguchi; M Kondo; T Yamamoto; M Nakamura; B Damdinsuren; H Wada; S Marubashi; A Miyamoto; K Dono; K Umeshita; S Nakamori; K Wakasa; M Monden
Journal:  Br J Cancer       Date:  2005-09-05       Impact factor: 7.640

View more
  2 in total

1.  Factors linked to longterm survival of patients with hepatocellular carcinoma accompanied by tumour thrombus in the major portal vein after surgical resection.

Authors:  Rumi Matono; Shohei Yoshiya; Takashi Motomura; Takeo Toshima; Hiroto Kayashima; Toshiro Masuda; Tomoharu Yoshizumi; Akinobu Taketomi; Ken Shirabe; Yoshihiko Maehara
Journal:  HPB (Oxford)       Date:  2012-02-03       Impact factor: 3.647

2.  Hepatocellular carcinoma, with portal thrombus after viral eradication, disappeared by 5-fluorouracil and interferon.

Authors:  Tomofumi Miura; Nobuaki Suzuki; Junichiro Nakamura; Satoshi Yamada; Tsutomu Miura; Masahiko Yanagi; Hiroyuki Usuda; Iwao Emura; Toru Takahashi
Journal:  World J Hepatol       Date:  2010-11-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.